Brain GABA Levels and Treatment Response in Major Depressive Disorder

Completed · Phase 4

Conditions studied: Major Depressive Disorder

In brief

This study will evaluate changes in brain gamma-aminobutyric acid (GABA) levels due to treatment with escitalopram in people with major depressive disorder.

Key facts

Study ID

NCT00464711

Run by

Massachusetts General Hospital

People needed

40

Starts

2006-09-01

Expected to finish

2009-09-01

Last updated by the study team

2017-01-04

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Meet diagnostic criteria for current Major Depressive Disorder
• Men or women aged 18-65
• Medication-free for one week prior to the start of the study
• Agrees to use an effective form of contraception throughout the study

You may not qualify if…

• Anyone who is suicidal
• Pregnant or breastfeeding women
• Anyone with a serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic or hematologic disease
• Anyone with a history of seizure disorder or hypothyroidism
• Anyone with a history of psychiatric disorders including bipolar disorder, schizophrenia, psychoses, or substance abuse (including alcohol abuse active within the last 12 months)
• Anyone with a history of intolerance or multiple adverse drug reactions or allergy to (es)citalopram.
• Patients who are currently taking medications active on GABA, including benzodiazepines.

Where it is running

• Depression Clinical and Research Program, Massachusetts General Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.